{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:08:41Z","timestamp":1789834121177,"version":"4.0.1"},"reference-count":193,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T00:00:00Z","timestamp":1742256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Private Universit\u00e4t Witten\/Herdecke gGmbH"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The global impact of emerging and re-emerging viral agents during epidemics and pandemics leads to serious health and economic burdens. Among the major emerging or re-emerging viruses include SARS-CoV-2, Ebola virus (EBOV), Monkeypox virus (Mpox), Hepatitis viruses, Zika virus, Avian flu, Influenza virus, Chikungunya virus (CHIKV), Dengue fever virus (DENV), West Nile virus, Rhabdovirus, Sandfly fever virus, Crimean-Congo hemorrhagic fever (CCHF) virus, and Rift Valley fever virus (RVFV). A comprehensive literature search was performed to identify existing studies, clinical trials, and reviews that discuss drug repositioning strategies for the treatment of emerging and re-emerging viral infections using databases, such as PubMed, Scholar Google, Scopus, and Web of Science. By utilizing drug repositioning, pharmaceutical companies can take advantage of a cost-effective, accelerated, and effective strategy, which in turn leads to the discovery of innovative treatment options for patients. In light of antiviral drug resistance and the high costs of developing novel antivirals, drug repositioning holds great promise for more rapid substitution of approved drugs. Main repositioned drugs have included chloroquine, ivermectin, dexamethasone, Baricitinib, tocilizumab, Mab114 (Ebanga\u2122), ZMapp (pharming), Artesunate, imiquimod, saquinavir, capmatinib, naldemedine, Trametinib, statins, celecoxib, naproxen, metformin, ruxolitinib, nitazoxanide, gemcitabine, Dorzolamide, Midodrine, Diltiazem, zinc acetate, suramin, 5-fluorouracil, quinine, minocycline, trifluoperazine, paracetamol, berbamine, Nifedipine, and chlorpromazine. This succinct review will delve into the topic of repositioned drugs that have been utilized to combat emerging and re-emerging viral pathogens.<\/jats:p>","DOI":"10.1007\/s11030-025-11131-8","type":"journal-article","created":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T11:16:05Z","timestamp":1742296565000},"page":"5465-5485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Drug repositioning as a promising approach for the eradication of emerging and re-emerging viral agents"],"prefix":"10.1007","volume":"29","author":[{"given":"Marwa","family":"Almulhim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdolmajid","family":"Ghasemian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Memariani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnaz","family":"Karami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7956-9739","authenticated-orcid":false,"given":"Asmaa S. A.","family":"Yassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2206-7236","authenticated-orcid":false,"given":"Athanasios","family":"Alexiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-874X","authenticated-orcid":false,"given":"Marios","family":"Papadakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7817-425X","authenticated-orcid":false,"given":"Gaber El-Saber","family":"Batiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,18]]},"reference":[{"key":"11131_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.715759","author":"B Chala","year":"2021","unstructured":"Chala B, Hamde F (2021) Emerging and re-emerging vector-borne infectious diseases and the challenges for control: a review. Front Public Health. https:\/\/doi.org\/10.3389\/fpubh.2021.715759","journal-title":"Front Public Health"},{"key":"11131_CR2","doi-asserted-by":"publisher","DOI":"10.3201\/eid2704.203569","author":"P-Y Nguyen","year":"2021","unstructured":"Nguyen P-Y, Ajisegiri WS, Costantino V, Chughtai AA, MacIntyre CR (2021) Reemergence of human monkeypox and declining population immunity in the context of urbanization, Nigeria, 2017\u20132020. Emerg Infect Dis. https:\/\/doi.org\/10.3201\/eid2704.203569","journal-title":"Emerg Infect Dis"},{"key":"11131_CR3","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.virol.2020.01.015","volume":"543","author":"P Pielnaa","year":"2020","unstructured":"Pielnaa P, Al-Saadawe M, Saro A, Dama MF, Zhou M, Huang Y, Huang J, Xia Z (2020) Zika virus-spread, epidemiology, genome, transmission cycle, clinical manifestation, associated challenges, vaccine and antiviral drug development. Virology 543:34\u201342. https:\/\/doi.org\/10.1016\/j.virol.2020.01.015","journal-title":"Virology"},{"key":"11131_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.coviro.2019.01.001","volume":"34","author":"Y-JS Huang","year":"2019","unstructured":"Huang Y-JS, Higgs S, Vanlandingham DL (2019) Emergence and re-emergence of mosquito-borne arboviruses. Curr Opin Virol 34:104\u2013109. https:\/\/doi.org\/10.1016\/j.coviro.2019.01.001","journal-title":"Curr Opin Virol"},{"issue":"6","key":"11131_CR5","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1016\/j.cell.2021.02.013","volume":"184","author":"L Lu","year":"2021","unstructured":"Lu L, Su S, Yang H, Jiang S (2021) Antivirals with common targets against highly pathogenic viruses. Cell 184(6):1604\u20131620. https:\/\/doi.org\/10.1016\/j.cell.2021.02.013","journal-title":"Cell"},{"issue":"10174","key":"11131_CR6","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S0140-6736(18)33132-5","volume":"393","author":"D Malvy","year":"2019","unstructured":"Malvy D, McElroy AK, de Clerck H, G\u00fcnther S, van Griensven J (2019) Ebola virus disease. The Lancet 393(10174):936\u2013948. https:\/\/doi.org\/10.1016\/S0140-6736(18)33132-5","journal-title":"The Lancet"},{"issue":"4","key":"11131_CR7","doi-asserted-by":"publisher","first-page":"e0281052","DOI":"10.1371\/journal.pone.0281052","volume":"18","author":"A Giacomelli","year":"2023","unstructured":"Giacomelli A, Righini E, Micheli V, Pinoli P, Bernasconi A, Rizzo A, Oreni L, Ridolfo AL, Antinori S, Ceri S, Rizzardini G (2023) SARS-CoV-2 viremia and COVID-19 mortality: a prospective observational study. PLoS ONE 18(4):e0281052. https:\/\/doi.org\/10.1371\/journal.pone.0281052","journal-title":"PLoS ONE"},{"issue":"11","key":"11131_CR8","doi-asserted-by":"publisher","first-page":"e0257979","DOI":"10.1371\/journal.pone.0257979","volume":"16","author":"MJ Satlin","year":"2021","unstructured":"Satlin MJ, Zucker J, Baer BR, Rajan M, Hupert N, Schang LM, Pinheiro LC, Shen Y, Sobieszczyk ME, Westblade LF, Goyal P, Wells MT, Sepulveda JL, Safford MM (2021) Changes in SARS-CoV-2 viral load and mortality during the initial wave of the pandemic in New York City. PLoS ONE 16(11):e0257979. https:\/\/doi.org\/10.1371\/journal.pone.0257979","journal-title":"PLoS ONE"},{"key":"11131_CR9","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2021.13","author":"E Mostafavi","year":"2021","unstructured":"Mostafavi E, Ghasemian A, Abdinasir A, Nematollahi Mahani SA, Rawaf S, Salehi Vaziri M, Gouya MM, Minh Nhu Nguyen T, Al-Awaidy S, Al-Ariqi L, Islam MM, Abd Farag EAB, Obtel M, Omondi Mala P, Matar GM, Asghar RJ, Barakat A, Sahak MN, Abdulmonem Mansouri M, Swaka A (2021) Emerging and re-emerging infectious diseases in the WHO Eastern Mediterranean region, 2001\u20132018. Int J Health Policy Manag. https:\/\/doi.org\/10.34172\/ijhpm.2021.13","journal-title":"Int J Health Policy Manag"},{"issue":"24","key":"11131_CR10","doi-asserted-by":"publisher","first-page":"8012","DOI":"10.26355\/eurrev_202112_27652","volume":"25","author":"SA Meo","year":"2021","unstructured":"Meo SA, Meo AS, Al-Jassir FF, Klonoff DC (2021) Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci 25(24):8012\u20138018. https:\/\/doi.org\/10.26355\/eurrev_202112_27652","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"6996","key":"11131_CR11","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/nature02759","volume":"430","author":"DM Morens","year":"2004","unstructured":"Morens DM, Folkers GK, Fauci AS (2004) The challenge of emerging and re-emerging infectious diseases. Nature 430(6996):242\u2013249. https:\/\/doi.org\/10.1038\/nature02759","journal-title":"Nature"},{"key":"11131_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02130","author":"M Trovato","year":"2020","unstructured":"Trovato M, Sartorius R, D\u2019Apice L, Manco R, De Berardinis P (2020) Viral emerging diseases: challenges in developing vaccination strategies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2020.02130","journal-title":"Front Immunol"},{"issue":"2","key":"11131_CR13","doi-asserted-by":"publisher","first-page":"135965352210827","DOI":"10.1177\/13596535221082773","volume":"27","author":"T Cihlar","year":"2022","unstructured":"Cihlar T, Mackman RL (2022) Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-19. Antivir Ther 27(2):135965352210827. https:\/\/doi.org\/10.1177\/13596535221082773","journal-title":"Antivir Ther"},{"issue":"5","key":"11131_CR14","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1021\/acscentsci.0c00489","volume":"6","author":"RT Eastman","year":"2020","unstructured":"Eastman RT, Roth JS, Brimacombe KR, Simeonov A, Shen M, Patnaik S, Hall MD (2020) Remdesivir: a review of its discovery and development leading to emergency use authorization for treatment of COVID-19. ACS Cent Sci 6(5):672\u2013683. https:\/\/doi.org\/10.1021\/acscentsci.0c00489","journal-title":"ACS Cent Sci"},{"key":"11131_CR15","doi-asserted-by":"publisher","first-page":"104858","DOI":"10.1016\/j.antiviral.2020.104858","volume":"181","author":"DW Hawman","year":"2020","unstructured":"Hawman DW, Haddock E, Meade-White K, Nardone G, Feldmann F, Hanley PW, Lovaglio J, Scott D, Komeno T, Nakajima N, Furuta Y, Gowen BB, Feldmann H (2020) Efficacy of favipiravir (T-705) against Crimean-Congo hemorrhagic fever virus infection in cynomolgus macaques. Antiviral Res 181:104858. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104858","journal-title":"Antiviral Res"},{"key":"11131_CR16","doi-asserted-by":"publisher","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","volume":"209","author":"K Shiraki","year":"2020","unstructured":"Shiraki K, Daikoku T (2020) Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther 209:107512. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107512","journal-title":"Pharmacol Ther"},{"issue":"6","key":"11131_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/14651858.CD012713.pub2","volume":"2018","author":"S Johnson","year":"2018","unstructured":"Johnson S, Henschke N, Maayan N, Mills I, Buckley BS, Kakourou A, Marshall R (2018) Ribavirin for treating Crimean Congo haemorrhagic fever. Cochrane Database System Rev 2018(6):1. https:\/\/doi.org\/10.1002\/14651858.CD012713.pub2","journal-title":"Cochrane Database System Rev"},{"issue":"6","key":"11131_CR18","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.3390\/microorganisms9061306","volume":"9","author":"J Mayor","year":"2021","unstructured":"Mayor J, Engler O, Rothenberger S (2021) Antiviral efficacy of Ribavirin and Favipiravir against Hantaan virus. Microorganisms 9(6):1306. https:\/\/doi.org\/10.3390\/microorganisms9061306","journal-title":"Microorganisms"},{"issue":"8","key":"11131_CR19","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1128\/AAC.49.8.3153-3162.2005","volume":"49","author":"WC Magee","year":"2005","unstructured":"Magee WC, Hostetler KY, Evans DH (2005) Mechanism of inhibition of vaccinia virus DNA polymerase by cidofovir diphosphate. Antimicrob Agents Chemother 49(8):3153\u20133162. https:\/\/doi.org\/10.1128\/AAC.49.8.3153-3162.2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"11131_CR20","doi-asserted-by":"publisher","first-page":"644","DOI":"10.1016\/j.vaccine.2019.10.049","volume":"38","author":"AT Russo","year":"2020","unstructured":"Russo AT, Berhanu A, Bigger CB, Prigge J, Silvera PM, Grosenbach DW, Hruby D (2020) Co-administration of tecovirimat and ACAM2000\u2122 in non-human primates: Effect of tecovirimat treatment on ACAM2000 immunogenicity and efficacy versus lethal monkeypox virus challenge. Vaccine 38(3):644\u2013654. https:\/\/doi.org\/10.1016\/j.vaccine.2019.10.049","journal-title":"Vaccine"},{"issue":"3","key":"11131_CR21","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1080\/14787210.2020.1819791","volume":"19","author":"AT Russo","year":"2021","unstructured":"Russo AT, Grosenbach DW, Chinsangaram J, Honeychurch KM, Long PG, Lovejoy C, Maiti B, Meara I, Hruby DE (2021) An overview of tecovirimat for smallpox treatment and expanded anti-orthopoxvirus applications. Expert Rev Anti Infect Ther 19(3):331\u2013344. https:\/\/doi.org\/10.1080\/14787210.2020.1819791","journal-title":"Expert Rev Anti Infect Ther"},{"key":"11131_CR22","doi-asserted-by":"publisher","first-page":"104708","DOI":"10.1016\/j.antiviral.2020.104708","volume":"175","author":"F Dragoni","year":"2020","unstructured":"Dragoni F, Boccuto A, Picarazzi F, Giannini A, Giammarino F, Saladini F, Mori M, Mastrangelo E, Zazzi M, Vicenti I (2020) Evaluation of sofosbuvir activity and resistance profile against West Nile virus in vitro. Antiviral Res 175:104708. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104708","journal-title":"Antiviral Res"},{"key":"11131_CR23","doi-asserted-by":"publisher","first-page":"104859","DOI":"10.1016\/j.antiviral.2020.104859","volume":"182","author":"NR Gardinali","year":"2020","unstructured":"Gardinali NR, Marchevsky RS, Oliveira JM, Pelajo-Machado M, Kugelmeier T, Castro MP, Silva ACA, Pinto DP, Fonseca LB, Vilhena LS, Pereira HM, Lima SMB, Miranda EH, Trindade GF, Linhares JHR, Silva SA, Melga\u00e7o JG, Alves AMB, Moran J et al (2020) Sofosbuvir shows a protective effect against vertical transmission of Zika virus and the associated congenital syndrome in rhesus monkeys. Antiviral Res 182:104859. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104859","journal-title":"Antiviral Res"},{"key":"11131_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.01056-22","author":"P Koszalka","year":"2022","unstructured":"Koszalka P, George A, Dhanasekaran V, Hurt AC, Subbarao K (2022) Effect of baloxavir and oseltamivir in combination on infection with influenza viruses with PA\/I38T or PA\/E23K substitutions in the ferret model. MBio. https:\/\/doi.org\/10.1128\/mbio.01056-22","journal-title":"MBio"},{"issue":"7","key":"11131_CR25","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.3201\/eid2707.204593","volume":"27","author":"T Mohan","year":"2021","unstructured":"Mohan T, Nguyen HT, Kniss K, Mishin VP, Merced-Morales AA, Laplante J, George K, Blevins P, Chesnokov A, De La Cruz JA, Kondor R, Wentworth DE, Gubareva LV (2021) Cluster of oseltamivir-resistant and hemagglutinin antigenically drifted influenza A(H1N1)pdm09 viruses, Texas, USA, January 2020. Emerg Infect Dis 27(7):1953\u20131957. https:\/\/doi.org\/10.3201\/eid2707.204593","journal-title":"Emerg Infect Dis"},{"issue":"2","key":"11131_CR26","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3851\/IMP3189","volume":"23","author":"M Higashiguchi","year":"2018","unstructured":"Higashiguchi M, Matsumoto T, Fujii T (2018) A meta-analysis of Laninamivir Octanoate for treatment and prophylaxis of influenza. Antivir Ther 23(2):157\u2013165. https:\/\/doi.org\/10.3851\/IMP3189","journal-title":"Antivir Ther"},{"issue":"2","key":"11131_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10156-012-0481-9","volume":"19","author":"S Kashiwagi","year":"2013","unstructured":"Kashiwagi S, Yoshida S, Yamaguchi H, Mitsui N, Tanigawa M, Shiozawa T, Yamaguchi F, Shiosakai K, Yamanouchi N (2013) Clinical efficacy of long-acting neuraminidase inhibitor laninamivir octanoate hydrate in postmarketing surveillance. J Infect Chemother 19(2):223\u2013232. https:\/\/doi.org\/10.1007\/s10156-012-0481-9","journal-title":"J Infect Chemother"},{"issue":"1","key":"11131_CR28","doi-asserted-by":"publisher","first-page":"e16028","DOI":"10.1371\/journal.pone.0016028","volume":"6","author":"G Orozovic","year":"2011","unstructured":"Orozovic G, Orozovic K, Lennerstrand J, Olsen B (2011) Detection of resistance mutations to antivirals Oseltamivir and Zanamivir in Avian influenza A viruses isolated from wild birds. PLoS ONE 6(1):e16028. https:\/\/doi.org\/10.1371\/journal.pone.0016028","journal-title":"PLoS ONE"},{"issue":"06","key":"11131_CR29","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1055\/s-0041-1733830","volume":"42","author":"E Palomba","year":"2021","unstructured":"Palomba E, Castelli V, Renisi G, Bandera A, Lombardi A, Gori A (2021) Antiviral treatments for influenza. Semin Respir Crit Care Med 42(06):859\u2013872. https:\/\/doi.org\/10.1055\/s-0041-1733830","journal-title":"Semin Respir Crit Care Med"},{"issue":"1","key":"11131_CR30","doi-asserted-by":"publisher","first-page":"3466","DOI":"10.1038\/s41598-019-39683-4","volume":"9","author":"K Taniguchi","year":"2019","unstructured":"Taniguchi K, Ando Y, Nobori H, Toba S, Noshi T, Kobayashi M, Kawai M, Yoshida R, Sato A, Shishido T, Naito A, Matsuno K, Okamatsu M, Sakoda Y, Kida H (2019) Inhibition of avian-origin influenza A(H7N9) virus by the novel cap-dependent endonuclease inhibitor baloxavir marboxil. Sci Rep 9(1):3466. https:\/\/doi.org\/10.1038\/s41598-019-39683-4","journal-title":"Sci Rep"},{"issue":"01\/02","key":"11131_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1055\/s-0029-1244814","volume":"135","author":"M Cornberg","year":"2010","unstructured":"Cornberg M, Manns M (2010) Entecavir\u2014M\u00f6glichkeiten und Grenzen einer effektiven Therapie der chronischen hepatitis B. DMW\u2014Deutsche Medizinische Wochenschrift 135(01\/02):32\u201337. https:\/\/doi.org\/10.1055\/s-0029-1244814","journal-title":"DMW\u2014Deutsche Medizinische Wochenschrift"},{"issue":"1","key":"11131_CR32","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/1743-422X-5-58","volume":"5","author":"MN Becker","year":"2008","unstructured":"Becker MN, Obraztsova M, Kern ER, Quenelle DC, Keith KA, Prichard MN, Luo M, Moyer RW (2008) Isolation and characterization of Cidofovir resistant vaccinia viruses. Virol J 5(1):58. https:\/\/doi.org\/10.1186\/1743-422X-5-58","journal-title":"Virol J"},{"issue":"1","key":"11131_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.5005\/jp-journals-10018-1163","volume":"6","author":"N Saeed","year":"2016","unstructured":"Saeed N (2016) Tackling HCV-3 in Asia: breakthroughs for efficient and cost-effective treatment strategies. Euroasian J Hepato-Gastroenterol 6(1):35\u201342. https:\/\/doi.org\/10.5005\/jp-journals-10018-1163","journal-title":"Euroasian J Hepato-Gastroenterol"},{"key":"11131_CR34","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/B978-0-12-384890-1.00013-3","volume-title":"Genetics and evolution of infectious disease","author":"A Vere Hodge","year":"2011","unstructured":"Vere Hodge A, Field HJ (2011) General mechanisms of antiviral resistance. Genetics and evolution of infectious disease. Elsevier, pp 339\u2013362"},{"issue":"10","key":"11131_CR35","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1080\/07391102.2020.1767210","volume":"39","author":"MMN Babadaei","year":"2021","unstructured":"Babadaei MMN, Hasan A, Vahdani Y, Bloukh SH, Sharifi M, Kachooei E, Haghighat S, Falahati M (2021) Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase. J Biomol Struct Dyn 39(10):3771\u20133779. https:\/\/doi.org\/10.1080\/07391102.2020.1767210","journal-title":"J Biomol Struct Dyn"},{"issue":"11","key":"11131_CR36","doi-asserted-by":"publisher","first-page":"4236","DOI":"10.4103\/jfmpc.jfmpc_578_21","volume":"10","author":"B Mohanty","year":"2021","unstructured":"Mohanty B, Sunder A, Satyanarayan B, Kumar M, Shukla R, Ahmed A (2021) Success rate of remdesivir, convalescent plasma, and tocilizumab in moderate to severe Covid-19 pneumonia. J Fam Med Primary Care 10(11):4236\u20134241. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_578_21","journal-title":"J Fam Med Primary Care"},{"key":"11131_CR37","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/DDDT.S356951","volume":"16","author":"S Moreno","year":"2022","unstructured":"Moreno S, Alc\u00e1zar-Navarrete B, Due\u00f1as C, Gonz\u00e1lez del Castillo J, Olalla J, Antela A (2022) Use of antivirals in SARS-CoV-2 infection: critical review of the role of remdesivir. Drug Des Dev Ther 16:827\u2013841. https:\/\/doi.org\/10.2147\/DDDT.S356951","journal-title":"Drug Des Dev Ther"},{"issue":"10","key":"11131_CR38","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.01155-21","volume":"65","author":"RT Schooley","year":"2021","unstructured":"Schooley RT, Carlin AF, Beadle JR, Valiaeva N, Zhang X-Q, Clark AE, McMillan RE, Leibel SL, McVicar RN, Xie J, Garretson AF, Smith VI, Murphy J, Hostetler KY (2021) Rethinking remdesivir: synthesis, antiviral activity, and pharmacokinetics of oral lipid prodrugs. Antimicrob Agents Chemother 65(10):1. https:\/\/doi.org\/10.1128\/AAC.01155-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"11131_CR39","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/S2468-1253(21)00398-8","volume":"7","author":"F Kateera","year":"2022","unstructured":"Kateera F, Shumbusho F, Manirambona L, Kabihizi J, Murangwa A, Serumondo J, Makuza JD, Nsanzimana S, Muvunyi CM, Kabakambira JD, Sylvain H, Camus G, Grant PM, Gupta N (2022) Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. Lancet Gastroenterol Hepatol 7(6):533\u2013541. https:\/\/doi.org\/10.1016\/S2468-1253(21)00398-8","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"11131_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/TCRM.S77788","volume":"861","author":"M Nkuize","year":"2016","unstructured":"Nkuize M, Serste T, Mulkay J-P, Buset M (2016) Combination ledipasvir-sofosbuvir for the treatment of chronic hepatitis C virus infection: a review and clinical perspective. Therap Clin Risk Manag 861:1. https:\/\/doi.org\/10.2147\/TCRM.S77788","journal-title":"Therap Clin Risk Manag"},{"issue":"3","key":"11131_CR41","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.anpedi.2018.07.007","volume":"90","author":"J Quintero","year":"2019","unstructured":"Quintero J, Juamp\u00e9rez J, Julio E, Cabello V, Mercadal-Hally M, Soler-Palac\u00edn P, Segarra \u00d3, Rodrigo C (2019) Combinaci\u00f3n de ledipasvir\/sofosbuvir como tratamiento de la infecci\u00f3n cr\u00f3nica por hepatitis C. Anales de Pediatr\u00eda 90(3):141\u2013147. https:\/\/doi.org\/10.1016\/j.anpedi.2018.07.007","journal-title":"Anales de Pediatr\u00eda"},{"issue":"1","key":"11131_CR42","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/jmv.24932","volume":"90","author":"B Snyder","year":"2018","unstructured":"Snyder B, Goebel S, Koide F, Ptak R, Kalkeri R (2018) Synergistic antiviral activity of Sofosbuvir and type-I interferons (\u03b1 and \u03b2) against Zika virus. J Med Virol 90(1):8\u201312. https:\/\/doi.org\/10.1002\/jmv.24932","journal-title":"J Med Virol"},{"issue":"4","key":"11131_CR43","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.jhep.2017.11.039","volume":"68","author":"K Agarwal","year":"2018","unstructured":"Agarwal K, Brunetto M, Seto WK, Lim Y-S, Fung S, Marcellin P, Ahn SH, Izumi N, Chuang W, Bae H, Sharma M, Janssen HLA, Pan CQ, \u00c7elen MK, Furusyo N, Shalimar Dr, Yoon KT, Trinh H, Flaherty JF et al (2018) 96 weeks treatment of tenofovir alafenamide vs tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 68(4):672\u2013681. https:\/\/doi.org\/10.1016\/j.jhep.2017.11.039","journal-title":"J Hepatol"},{"issue":"6","key":"11131_CR44","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1007\/s12072-021-10262-y","volume":"15","author":"HY Chon","year":"2021","unstructured":"Chon HY, Ahn SH, Kim YJ, Yoon J-H, Lee J-H, Sinn DH, Kim SU (2021) Efficacy of entecavir, tenofovir disoproxil fumarate, and tenofovir alafenamide in treatment-naive hepatitis B patients. Hep Int 15(6):1328\u20131336. https:\/\/doi.org\/10.1007\/s12072-021-10262-y","journal-title":"Hep Int"},{"issue":"9","key":"11131_CR45","doi-asserted-by":"publisher","first-page":"e3324","DOI":"10.1093\/cid\/ciaa1939","volume":"73","author":"Q-L Zeng","year":"2021","unstructured":"Zeng Q-L, Yu Z-J, Ji F, Li G-M, Zhang G-F, Xu J-H, Chen Z-M, Cui G-L, Li W, Zhang D-W, Li J, Lv J, Li Z-Q, Liang H-X, Sun C-Y, Pan Y-J, Liu Y-M, Wang F-S (2021) Tenofovir alafenamide to prevent perinatal hepatitis B transmission: a multicenter, prospective. Observ Study Clin Infect Dis 73(9):e3324\u2013e3332. https:\/\/doi.org\/10.1093\/cid\/ciaa1939","journal-title":"Observ Study Clin Infect Dis"},{"issue":"33","key":"11131_CR46","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1016\/j.vaccine.2018.04.003","volume":"37","author":"M Smreczak","year":"2019","unstructured":"Smreczak M, Or\u0142owska A, Marzec A, Tr\u0119bas P, Kycko A, Reichert M, Koraka P, Osterhaus ADME, \u017bmudzi\u0144ski JF (2019) The effect of combined drugs therapy on the course of clinical rabies infection in a murine model. Vaccine 37(33):4701\u20134709. https:\/\/doi.org\/10.1016\/j.vaccine.2018.04.003","journal-title":"Vaccine"},{"issue":"9","key":"11131_CR47","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/jphp.13273","volume":"72","author":"J-P Jourdan","year":"2020","unstructured":"Jourdan J-P, Bureau R, Rochais C, Dallemagne P (2020) Drug repositioning: a brief overview. J Pharm Pharmacol 72(9):1145\u20131151. https:\/\/doi.org\/10.1111\/jphp.13273","journal-title":"J Pharm Pharmacol"},{"issue":"1","key":"11131_CR48","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"S Pushpakom","year":"2019","unstructured":"Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, Norris A, Sanseau P, Cavalla D, Pirmohamed M (2019) Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 18(1):41\u201358. https:\/\/doi.org\/10.1038\/nrd.2018.168","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"11131_CR49","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1146\/annurev-chembioeng-060817-084355","volume":"9","author":"CL Burcham","year":"2018","unstructured":"Burcham CL, Florence AJ, Johnson MD (2018) Continuous manufacturing in pharmaceutical process development and manufacturing. Annu Rev Chem Biomol Eng 9(1):253\u2013281. https:\/\/doi.org\/10.1146\/annurev-chembioeng-060817-084355","journal-title":"Annu Rev Chem Biomol Eng"},{"issue":"11","key":"11131_CR50","doi-asserted-by":"publisher","first-page":"e2239336","DOI":"10.1001\/jamanetworkopen.2022.39336","volume":"5","author":"AN Monge","year":"2022","unstructured":"Monge AN, Sigelman DW, Temple RJ, Chahal HS (2022) Use of US food and drug administration expedited drug development and review programs by orphan and nonorphan novel drugs approved from 2008 to 2021. JAMA Netw Open 5(11):e2239336. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.39336","journal-title":"JAMA Netw Open"},{"issue":"2","key":"11131_CR51","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41390-023-02878-7","volume":"95","author":"SA Hoffman","year":"2024","unstructured":"Hoffman SA, Maldonado YA (2024) Emerging and re-emerging pediatric viral diseases: a continuing global challenge. Pediatr Res 95(2):480\u2013487. https:\/\/doi.org\/10.1038\/s41390-023-02878-7","journal-title":"Pediatr Res"},{"issue":"12","key":"11131_CR52","doi-asserted-by":"publisher","first-page":"2637","DOI":"10.1007\/s42399-020-00610-8","volume":"2","author":"MH Ahmed","year":"2020","unstructured":"Ahmed MH, Hassan A (2020) Dexamethasone for the treatment of coronavirus disease (COVID-19): a review. SN Compr Clin Med 2(12):2637\u20132646. https:\/\/doi.org\/10.1007\/s42399-020-00610-8","journal-title":"SN Compr Clin Med"},{"issue":"2","key":"11131_CR53","doi-asserted-by":"publisher","first-page":"00129","DOI":"10.1183\/23120541.00129-2022","volume":"8","author":"J Kocks","year":"2022","unstructured":"Kocks J, Kerkhof M, Scherpenisse J, van de Maat A, van Geer-Postmus I, le R\u00fctte T, Schaart J, Gans ROB, Kerstjens HAM (2022) A potential harmful effect of dexamethasone in non-severe COVID-19: results from the COPPER-pilot study. ERJ Open Res 8(2):00129\u201302022. https:\/\/doi.org\/10.1183\/23120541.00129-2022","journal-title":"ERJ Open Res"},{"issue":"4","key":"11131_CR54","doi-asserted-by":"publisher","first-page":"S18","DOI":"10.1016\/j.semarthrit.2015.11.007","volume":"45","author":"F Rannou","year":"2016","unstructured":"Rannou F, Pelletier J-P, Martel-Pelletier J (2016) Efficacy and safety of topical NSAIDs in the management of osteoarthritis: evidence from real-life setting trials and surveys. Semin Arthritis Rheum 45(4):S18\u2013S21. https:\/\/doi.org\/10.1016\/j.semarthrit.2015.11.007","journal-title":"Semin Arthritis Rheum"},{"issue":"24","key":"11131_CR55","doi-asserted-by":"publisher","first-page":"e7126","DOI":"10.1097\/MD.0000000000007126","volume":"96","author":"J Meng","year":"2017","unstructured":"Meng J, Li L (2017) The efficiency and safety of dexamethasone for pain control in total joint arthroplasty. Medicine 96(24):e7126. https:\/\/doi.org\/10.1097\/MD.0000000000007126","journal-title":"Medicine"},{"key":"11131_CR56","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28680","author":"D Dupuis","year":"2022","unstructured":"Dupuis D, Fritz K, Ike E, Arogundade O, Adewara EO, Monday EO, Ayinde BO (2022) Current use of Baricitinib in COVID-19 treatment and its future: an updated literature review. Cureus. https:\/\/doi.org\/10.7759\/cureus.28680","journal-title":"Cureus"},{"issue":"14","key":"11131_CR57","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.2174\/1389201024666230302113110","volume":"24","author":"Y Ratan","year":"2023","unstructured":"Ratan Y, Rajput A, Jain V, Mishra DK, Gautam RK, Pareek A (2023) Promising repurposed antiviral molecules to combat SARS-CoV-2: a review. Curr Pharm Biotechnol 24(14):1727\u20131739. https:\/\/doi.org\/10.2174\/1389201024666230302113110","journal-title":"Curr Pharm Biotechnol"},{"key":"11131_CR58","doi-asserted-by":"publisher","first-page":"104826","DOI":"10.1016\/j.compbiomed.2021.104826","volume":"137","author":"C Sonkar","year":"2021","unstructured":"Sonkar C, Doharey PK, Rathore AS, Singh V, Kashyap D, Sahoo AK, Mittal N, Sharma B, Jha HC (2021) Repurposing of gastric cancer drugs against COVID-19. Comput Biol Med 137:104826. https:\/\/doi.org\/10.1016\/j.compbiomed.2021.104826","journal-title":"Comput Biol Med"},{"issue":"17","key":"11131_CR59","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","volume":"77","author":"LJ Scott","year":"2017","unstructured":"Scott LJ (2017) Tocilizumab: a review in rheumatoid arthritis. Drugs 77(17):1865\u20131879. https:\/\/doi.org\/10.1007\/s40265-017-0829-7","journal-title":"Drugs"},{"issue":"6","key":"11131_CR60","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1111\/fcp.12662","volume":"35","author":"A Truffot","year":"2021","unstructured":"Truffot A, Gautier-Veyret E, Baillet A, Jourdil J, Stanke-Labesque F, Gottenberg J (2021) Variability of rituximab and tocilizumab trough concentrations in patients with rheumatoid arthritis. Fundam Clin Pharmacol 35(6):1090\u20131099. https:\/\/doi.org\/10.1111\/fcp.12662","journal-title":"Fundam Clin Pharmacol"},{"key":"11131_CR61","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.825749","author":"E Abidi","year":"2022","unstructured":"Abidi E, El Nekidy WS, Alefishat E, Rahman N, Petroianu GA, El-Lababidi R, Mallat J (2022) Tocilizumab and COVID-19: timing of administration and efficacy. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.825749","journal-title":"Front Pharmacol"},{"issue":"8","key":"11131_CR62","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3390\/biomedicines10081861","volume":"10","author":"P Mokhtary","year":"2022","unstructured":"Mokhtary P, Pourhashem Z, Mehrizi AA, Sala C, Rappuoli R (2022) Recent progress in the discovery and development of monoclonal antibodies against viral infections. Biomedicines 10(8):1861. https:\/\/doi.org\/10.3390\/biomedicines10081861","journal-title":"Biomedicines"},{"issue":"15","key":"11131_CR63","doi-asserted-by":"publisher","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","volume":"184","author":"R Copin","year":"2021","unstructured":"Copin R, Baum A, Wloga E, Pascal KE, Giordano S, Fulton BO, Zhou A, Negron N, Lanza K, Chan N, Coppola A, Chiu J, Ni M, Wei Y, Atwal GS, Hernandez AR, Saotome K, Zhou Y, Franklin MC et al (2021) The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies. Cell 184(15):3949-3961.e11. https:\/\/doi.org\/10.1016\/j.cell.2021.06.002","journal-title":"Cell"},{"issue":"20","key":"11131_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1073\/pnas.2120976119","volume":"119","author":"JL Torres","year":"2022","unstructured":"Torres JL, Ozorowski G, Andreano E, Liu H, Copps J, Piccini G, Donnici L, Conti M, Planchais C, Planas D, Manganaro N, Pantano E, Paciello I, Pileri P, Bruel T, Montomoli E, Mouquet H, Schwartz O, Sala C et al (2022) Structural insights of a highly potent pan-neutralizing SARS-CoV-2 human monoclonal antibody. Proc Natl Acad Sci 119(20):1. https:\/\/doi.org\/10.1073\/pnas.2120976119","journal-title":"Proc Natl Acad Sci"},{"issue":"6","key":"11131_CR65","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.pt.2017.02.004","volume":"33","author":"R Laing","year":"2017","unstructured":"Laing R, Gillan V, Devaney E (2017) Ivermectin\u2014old drug, new tricks? Trends Parasitol 33(6):463\u2013472. https:\/\/doi.org\/10.1016\/j.pt.2017.02.004","journal-title":"Trends Parasitol"},{"key":"11131_CR66","doi-asserted-by":"publisher","first-page":"104787","DOI":"10.1016\/j.antiviral.2020.104787","volume":"178","author":"L Caly","year":"2020","unstructured":"Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 178:104787. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104787","journal-title":"Antiviral Res"},{"issue":"1","key":"11131_CR67","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1186\/s12879-022-07589-8","volume":"22","author":"MS Marcolino","year":"2022","unstructured":"Marcolino MS, Meira KC, Guimar\u00e3es NS, Motta PP, Chagas VS, Kelles SMB, de S\u00e1 LC, Valacio RA, Ziegelmann PK (2022) Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype. BMC Infect Dis 22(1):639. https:\/\/doi.org\/10.1186\/s12879-022-07589-8","journal-title":"BMC Infect Dis"},{"key":"11131_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taab005","author":"S Rakedzon","year":"2021","unstructured":"Rakedzon S, Neuberger A, Domb AJ, Petersiel N, Schwartz E (2021) From hydroxychloroquine to ivermectin: what are the anti-viral properties of anti-parasitic drugs to combat SARS-CoV-2? J Travel Med. https:\/\/doi.org\/10.1093\/jtm\/taab005","journal-title":"J Travel Med"},{"issue":"8","key":"11131_CR69","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nri1154","volume":"3","author":"H Feldmann","year":"2003","unstructured":"Feldmann H, Jones S, Klenk H-D, Schnittler H-J (2003) Ebola virus: from discovery to vaccine. Nat Rev Immunol 3(8):677\u2013685. https:\/\/doi.org\/10.1038\/nri1154","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"11131_CR70","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","volume":"12","author":"L Baseler","year":"2017","unstructured":"Baseler L, Chertow DS, Johnson KM, Feldmann H, Morens DM (2017) The pathogenesis of Ebola virus disease. Annu Rev Pathol 12(1):387\u2013418. https:\/\/doi.org\/10.1146\/annurev-pathol-052016-100506","journal-title":"Annu Rev Pathol"},{"issue":"1","key":"11131_CR71","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41572-020-0147-3","volume":"6","author":"ST Jacob","year":"2020","unstructured":"Jacob ST, Crozier I, Fischer WA, Hewlett A, Kraft CS, de La Vega M-A, Soka MJ, Wahl V, Griffiths A, Bollinger L, Kuhn JH (2020) Ebola virus disease. Nat Rev Dis Primers 6(1):13. https:\/\/doi.org\/10.1038\/s41572-020-0147-3","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"11131_CR72","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1146\/annurev-virology-092818-015708","volume":"6","author":"W Furuyama","year":"2019","unstructured":"Furuyama W, Marzi A (2019) Ebola virus: pathogenesis and countermeasure development. Annu Rev Virol 6(1):435\u2013458. https:\/\/doi.org\/10.1146\/annurev-virology-092818-015708","journal-title":"Annu Rev Virol"},{"issue":"7","key":"11131_CR73","doi-asserted-by":"publisher","first-page":"2189","DOI":"10.4103\/jfmpc.jfmpc_297_19","volume":"8","author":"S Hasan","year":"2019","unstructured":"Hasan S, Ahmad S, Masood R, Saeed S (2019) Ebola virus: a global public health menace\u2014a narrative review. J Fam Med Primary Care 8(7):2189. https:\/\/doi.org\/10.4103\/jfmpc.jfmpc_297_19","journal-title":"J Fam Med Primary Care"},{"issue":"7610","key":"11131_CR74","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature18615","volume":"535","author":"Y Zhao","year":"2016","unstructured":"Zhao Y, Ren J, Harlos K, Jones DM, Zeltina A, Bowden TA, Padilla-Parra S, Fry EE, Stuart DI (2016) Toremifene interacts with and destabilizes the Ebola virus glycoprotein. Nature 535(7610):169\u2013172. https:\/\/doi.org\/10.1038\/nature18615","journal-title":"Nature"},{"issue":"21","key":"11131_CR75","doi-asserted-by":"publisher","first-page":"10982","DOI":"10.1128\/JVI.01490-15","volume":"89","author":"E Davidson","year":"2015","unstructured":"Davidson E, Bryan C, Fong RH, Barnes T, Pfaff JM, Mabila M, Rucker JB, Doranz BJ (2015) Mechanism of binding to Ebola virus glycoprotein by the ZMapp, ZMAb, and MB-003 cocktail antibodies. J Virol 89(21):10982\u201310992. https:\/\/doi.org\/10.1128\/JVI.01490-15","journal-title":"J Virol"},{"issue":"6","key":"11131_CR76","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1093\/infdis\/jiy230","volume":"218","author":"B Yang","year":"2018","unstructured":"Yang B, Schaefer A, Wang Y-Y, McCallen J, Lee P, Newby JM, Arora H, Kumar PA, Zeitlin L, Whaley KJ, McKinley SA, Fischer WA, Harit D, Lai SK (2018) ZMapp reinforces the airway mucosal barrier against Ebola virus. J Infect Dis 218(6):901\u2013910. https:\/\/doi.org\/10.1093\/infdis\/jiy230","journal-title":"J Infect Dis"},{"issue":"3","key":"11131_CR77","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.jiph.2022.01.005","volume":"15","author":"P Sivanandy","year":"2022","unstructured":"Sivanandy P, Jun PH, Man LW, Wei NS, Mun NFK, Yii CAJ, Ying CCX (2022) A systematic review of Ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of Ebola virus disease by the US Food and Drug Administration from 2016 to 2020. J Infect Public Health 15(3):285\u2013292. https:\/\/doi.org\/10.1016\/j.jiph.2022.01.005","journal-title":"J Infect Public Health"},{"issue":"7","key":"11131_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/ofid\/ofz250","volume":"6","author":"SC Garbern","year":"2019","unstructured":"Garbern SC, Yam D, Aluisio AR, Cho DK, Kennedy SB, Massaquoi M, Sahr F, Perera SM, Levine AC, Liu T (2019) Effect of mass artesunate-amodiaquine distribution on mortality of patients with Ebola virus disease during west African outbreak. Open Forum Infect Dis 6(7):1. https:\/\/doi.org\/10.1093\/ofid\/ofz250","journal-title":"Open Forum Infect Dis"},{"issue":"1","key":"11131_CR79","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s12879-021-06811-3","volume":"22","author":"L Abel","year":"2022","unstructured":"Abel L, Perera SM, Yam D, Garbern S, Kennedy SB, Massaquoi M, Sahr F, Woldemichael D, Liu T, Levine AC, Aluisio AR (2022) Association between oral antimalarial medication administration and mortality among patients with Ebola virus disease: a multisite cohort study. BMC Infect Dis 22(1):71. https:\/\/doi.org\/10.1186\/s12879-021-06811-3","journal-title":"BMC Infect Dis"},{"issue":"8","key":"11131_CR80","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1038\/s41551-021-00718-9","volume":"5","author":"L Si","year":"2021","unstructured":"Si L, Bai H, Rodas M, Cao W, Oh CY, Jiang A, Moller R, Hoagland D, Oishi K, Horiuchi S, Uhl S, Blanco-Melo D, Albrecht RA, Liu W-C, Jordan T, Nilsson-Payant BE, Golynker I, Frere J, Logue J et al (2021) A human-airway-on-a-chip for the rapid identification of candidate antiviral therapeutics and prophylactics. Nat Biomed Eng 5(8):815\u2013829. https:\/\/doi.org\/10.1038\/s41551-021-00718-9","journal-title":"Nat Biomed Eng"},{"key":"11131_CR81","doi-asserted-by":"publisher","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","volume":"177","author":"F Touret","year":"2020","unstructured":"Touret F, de Lamballerie X (2020) Of chloroquine and COVID-19. Antiviral Res 177:104762. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104762","journal-title":"Antiviral Res"},{"key":"11131_CR82","doi-asserted-by":"publisher","unstructured":"Widener RW, Whitley RJ (2014) Herpes simplex virus, pp 251\u2013263. https:\/\/doi.org\/10.1016\/B978-0-444-53488-0.00011-0","DOI":"10.1016\/B978-0-444-53488-0.00011-0"},{"key":"11131_CR83","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2054","author":"X Xu","year":"2019","unstructured":"Xu X, Zhang Y, Li Q (2019) Characteristics of herpes simplex virus infection and pathogenesis suggest a strategy for vaccine development. Rev Med Virol. https:\/\/doi.org\/10.1002\/rmv.2054","journal-title":"Rev Med Virol"},{"issue":"6","key":"11131_CR84","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/QCO.0000000000000288","volume":"29","author":"J Piret","year":"2016","unstructured":"Piret J, Boivin G (2016) Antiviral resistance in herpes simplex virus and varicella-zoster virus infections: diagnosis and management. Curr Opin Infect Dis 29(6):654\u2013662. https:\/\/doi.org\/10.1097\/QCO.0000000000000288","journal-title":"Curr Opin Infect Dis"},{"issue":"12","key":"11131_CR85","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.3390\/v12121356","volume":"12","author":"S Andreu","year":"2020","unstructured":"Andreu S, Ripa I, Bello-Morales R, L\u00f3pez-Guerrero JA (2020) Valproic acid and its amidic derivatives as new antivirals against alphaherpesviruses. Viruses 12(12):1356. https:\/\/doi.org\/10.3390\/v12121356","journal-title":"Viruses"},{"key":"11131_CR86","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.virusres.2016.01.009","volume":"214","author":"AJ Crespillo","year":"2016","unstructured":"Crespillo AJ, Praena B, Bello-Morales R, Lerma L, V\u00e1zquez-Calvo A, Mart\u00edn-Acebes MA, Tabar\u00e9s E, Sobrino F, L\u00f3pez-Guerrero JA (2016) Inhibition of herpes virus infection in oligodendrocyte cultured cells by valproic acid. Virus Res 214:71\u201379. https:\/\/doi.org\/10.1016\/j.virusres.2016.01.009","journal-title":"Virus Res"},{"issue":"9","key":"11131_CR87","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1111\/1346-8138.16446","volume":"49","author":"C Leeyaphan","year":"2022","unstructured":"Leeyaphan C, Nanchaipruek Y, Phinyo P (2022) Therapeutic outcomes and prognostic factors in patients with hypertrophic herpes simplex infection treated with imiquimod: a systematic review and meta-analysis of individual patient data from case reports and case series. J Dermatol 49(9):879\u2013886. https:\/\/doi.org\/10.1111\/1346-8138.16446","journal-title":"J Dermatol"},{"issue":"5","key":"11131_CR88","doi-asserted-by":"publisher","first-page":"621","DOI":"10.6061\/clinics\/2013(05)07","volume":"68","author":"GF da Cunha","year":"2013","unstructured":"da Cunha GF, de Souza FHC, Levy-Neto M, Shinjo SK (2013) Chloroquine diphosphate: a risk factor for herpes zoster in patients with dermatomyositis\/polymyositis. Clinics 68(5):621\u2013627. https:\/\/doi.org\/10.6061\/clinics\/2013(05)07","journal-title":"Clinics"},{"issue":"10","key":"11131_CR89","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1038\/s41577-022-00775-4","volume":"22","author":"F-M Lum","year":"2022","unstructured":"Lum F-M, Torres-Ruesta A, Tay MZ, Lin RTP, Lye DC, R\u00e9nia L, Ng LFP (2022) Monkeypox: disease epidemiology, host immunity and clinical interventions. Nat Rev Immunol 22(10):597\u2013613. https:\/\/doi.org\/10.1038\/s41577-022-00775-4","journal-title":"Nat Rev Immunol"},{"key":"11131_CR90","doi-asserted-by":"publisher","first-page":"102855","DOI":"10.1016\/j.jaut.2022.102855","volume":"131","author":"N Kumar","year":"2022","unstructured":"Kumar N, Acharya A, Gendelman HE, Byrareddy SN (2022) The 2022 outbreak and the pathobiology of the monkeypox virus. J Autoimmun 131:102855. https:\/\/doi.org\/10.1016\/j.jaut.2022.102855","journal-title":"J Autoimmun"},{"issue":"9","key":"11131_CR91","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s11274-019-2719-5","volume":"35","author":"H Memariani","year":"2019","unstructured":"Memariani H, Memariani M, Ghasemian A (2019) An overview on anti-biofilm properties of quercetin against bacterial pathogens. World J Microbiol Biotechnol 35(9):143. https:\/\/doi.org\/10.1007\/s11274-019-2719-5","journal-title":"World J Microbiol Biotechnol"},{"issue":"2","key":"11131_CR92","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1007\/s11845-022-03052-4","volume":"192","author":"M Memariani","year":"2023","unstructured":"Memariani M, Memariani H (2023) Multinational monkeypox outbreak: what do we know and what should we do? Irish J Med Sci (1971-) 192(2):721\u2013722. https:\/\/doi.org\/10.1007\/s11845-022-03052-4","journal-title":"Irish J Med Sci (1971-)"},{"issue":"3","key":"11131_CR93","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s11030-023-10636-4","volume":"28","author":"V Srivastava","year":"2024","unstructured":"Srivastava V, Naik B, Godara P, Das D, Mattaparthi VSK, Prusty D (2024) Identification of FDA-approved drugs with triple targeting mode of action for the treatment of monkeypox: a high throughput virtual screening study. Mol Divers 28(3):1093\u20131107. https:\/\/doi.org\/10.1007\/s11030-023-10636-4","journal-title":"Mol Divers"},{"key":"11131_CR94","first-page":"1","volume-title":"Overview of influenza viruses","author":"S Pleschka","year":"2012","unstructured":"Pleschka S (2012) Overview of influenza viruses. Springer, pp 1\u201320"},{"issue":"8","key":"11131_CR95","doi-asserted-by":"publisher","first-page":"791","DOI":"10.2174\/156652405774962281","volume":"5","author":"D Kobasa","year":"2005","unstructured":"Kobasa D, Kawaoka Y (2005) Emerging influenza viruses: past and present. Curr Mol Med 5(8):791\u2013803. https:\/\/doi.org\/10.2174\/156652405774962281","journal-title":"Curr Mol Med"},{"key":"11131_CR96","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00531","author":"A Pizzorno","year":"2019","unstructured":"Pizzorno A, Padey B, Terrier O, Rosa-Calatrava M (2019) Drug repurposing approaches for the treatment of influenza viral infection: reviving old drugs to fight against a long-lived enemy. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2019.00531","journal-title":"Front Immunol"},{"issue":"5","key":"11131_CR97","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/tbed.14458","volume":"69","author":"Y Guo","year":"2022","unstructured":"Guo Y, Ding P, Li Y, Zhang Y, Zheng Y, Yu M, Suzuki Y, Zhang H, Ping J (2022) Genetic and biological properties of H10N3 avian influenza viruses: a potential pandemic candidate? Transboundary Emerg Dis 69(5):1. https:\/\/doi.org\/10.1111\/tbed.14458","journal-title":"Transboundary Emerg Dis"},{"issue":"7250","key":"11131_CR98","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/nature08182","volume":"459","author":"GJD Smith","year":"2009","unstructured":"Smith GJD, Vijaykrishna D, Bahl J, Lycett SJ, Worobey M, Pybus OG, Ma SK, Cheung CL, Raghwani J, Bhatt S, Peiris JSM, Guan Y, Rambaut A (2009) Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic. Nature 459(7250):1122\u20131125. https:\/\/doi.org\/10.1038\/nature08182","journal-title":"Nature"},{"issue":"4","key":"11131_CR99","doi-asserted-by":"publisher","first-page":"JJID.2021.751","DOI":"10.7883\/yoken.JJID.2021.751","volume":"75","author":"E Takashita","year":"2022","unstructured":"Takashita E, Morita H, Nagata S, Shirakura M, Fujisaki S, Miura H, Takayama I, Arita T, Suzuki Y, Yamaoka M, Tanikawa T, Tsunekuni R, Mine J, Sakuma S, Uchida Y, Shibata A, Iwanaka M, Kishida N, Nakamura K et al (2022) Antiviral susceptibilities of Avian influenza A(H5), A(H7), and A(H9) viruses isolated in Japan. Jpn J Infect Dis 75(4):JJID.2021.751. https:\/\/doi.org\/10.7883\/yoken.JJID.2021.751","journal-title":"Jpn J Infect Dis"},{"issue":"7","key":"11131_CR100","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/AAC.00352-20","volume":"64","author":"JJ Lim","year":"2020","unstructured":"Lim JJ, Nilsson AC, Silverman M, Assy N, Kulkarni P, McBride JM, Deng R, Li C, Yang X, Nguyen A, Horn P, Maia M, Castro A, Peck MC, Galanter J, Chu T, Newton EM, Tavel JA (2020) A phase 2 randomized, double-blind, placebo-controlled trial of MHAA4549A, a monoclonal antibody, plus oseltamivir in patients hospitalized with severe influenza A virus infection. Antimicrob Agents Chemother 64(7):1. https:\/\/doi.org\/10.1128\/AAC.00352-20","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"11131_CR101","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1080\/19420862.2016.1167294","volume":"8","author":"P Gupta","year":"2016","unstructured":"Gupta P, Kamath AV, Park S, Chiu H, Lutman J, Maia M, Tan M-W, Xu M, Swem L, Deng R (2016) Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A. MAbs 8(5):991\u2013997. https:\/\/doi.org\/10.1080\/19420862.2016.1167294","journal-title":"MAbs"},{"issue":"1","key":"11131_CR102","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-020-0206-5","volume":"5","author":"X Wang","year":"2020","unstructured":"Wang X, Zhou P, Wu M, Yang K, Guo J, Wang X, Li J, Fang Z, Wang G, Xing M, Zhou D (2020) Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection. NPJ Vaccines 5(1):57. https:\/\/doi.org\/10.1038\/s41541-020-0206-5","journal-title":"NPJ Vaccines"},{"issue":"24","key":"11131_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/JVI.01603-17","volume":"91","author":"TC Sutton","year":"2017","unstructured":"Sutton TC, Lamirande EW, Bock KW, Moore IN, Koudstaal W, Rehman M, Weverling GJ, Goudsmit J, Subbarao K (2017) In vitro neutralization is not predictive of prophylactic efficacy of broadly neutralizing monoclonal antibodies CR6261 and CR9114 against lethal H2 influenza virus challenge in mice. J Virol 91(24):1. https:\/\/doi.org\/10.1128\/JVI.01603-17","journal-title":"J Virol"},{"issue":"6","key":"11131_CR104","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/v14061325","volume":"14","author":"C Dietz","year":"2022","unstructured":"Dietz C, Maasoumy B (2022) Direct-acting antiviral agents for hepatitis C virus infection\u2014from drug discovery to successful implementation in clinical practice. Viruses 14(6):1325. https:\/\/doi.org\/10.3390\/v14061325","journal-title":"Viruses"},{"key":"11131_CR105","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.bpobgyn.2020.03.009","volume":"68","author":"MT Seto","year":"2020","unstructured":"Seto MT, Cheung KW, Hung IFN (2020) Management of viral hepatitis A, C, D and E in pregnancy. Best Pract Res Clin Obstet Gynaecol 68:44\u201353. https:\/\/doi.org\/10.1016\/j.bpobgyn.2020.03.009","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"37","key":"11131_CR106","doi-asserted-by":"publisher","first-page":"5543","DOI":"10.3748\/wjg.v26.i37.5543","volume":"26","author":"AT Aslan","year":"2020","unstructured":"Aslan AT, Balaban HY (2020) Hepatitis E virus: epidemiology, diagnosis, clinical manifestations, and treatment. World J Gastroenterol 26(37):5543\u20135560. https:\/\/doi.org\/10.3748\/wjg.v26.i37.5543","journal-title":"World J Gastroenterol"},{"key":"11131_CR107","doi-asserted-by":"publisher","first-page":"104967","DOI":"10.1016\/j.antiviral.2020.104967","volume":"184","author":"Y Li","year":"2020","unstructured":"Li Y, Li P, Li Y, Zhang R, Yu P, Ma Z, Kainov DE, de Man RA, Peppelenbosch MP, Pan Q (2020) Drug screening identified gemcitabine inhibiting hepatitis E virus by inducing interferon-like response via activation of STAT1 phosphorylation. Antiviral Res 184:104967. https:\/\/doi.org\/10.1016\/j.antiviral.2020.104967","journal-title":"Antiviral Res"},{"issue":"5","key":"11131_CR108","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s00705-023-05770-1","volume":"168","author":"N Bhise","year":"2023","unstructured":"Bhise N, Agarwal M, Thakur N, Akshay PS, Cherian S, Lole K (2023) Repurposing of artesunate, an antimalarial drug, as a potential inhibitor of hepatitis E virus. Adv Virol 168(5):147. https:\/\/doi.org\/10.1007\/s00705-023-05770-1","journal-title":"Adv Virol"},{"issue":"5","key":"11131_CR109","doi-asserted-by":"publisher","first-page":"969","DOI":"10.3390\/v14050969","volume":"14","author":"TYV de Lima Cavalcanti","year":"2022","unstructured":"de Lima Cavalcanti TYV, Pereira MR, de Paula SO, de Franca RFO (2022) A review on chikungunya virus epidemiology, pathogenesis and current vaccine development. Viruses 14(5):969. https:\/\/doi.org\/10.3390\/v14050969","journal-title":"Viruses"},{"issue":"4","key":"11131_CR110","doi-asserted-by":"publisher","first-page":"e107","DOI":"10.1016\/S1473-3099(16)30385-1","volume":"17","author":"FJ Burt","year":"2017","unstructured":"Burt FJ, Chen W, Miner JJ, Lenschow DJ, Merits A, Schnettler E, Kohl A, Rudd PA, Taylor A, Herrero LJ, Zaid A, Ng LFP, Mahalingam S (2017) Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen. Lancet Infect Dis 17(4):e107\u2013e117. https:\/\/doi.org\/10.1016\/S1473-3099(16)30385-1","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"11131_CR111","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/microorganisms10020354","volume":"10","author":"J Phadungsombat","year":"2022","unstructured":"Phadungsombat J, Imad HA, Nakayama EE, Leaungwutiwong P, Ramasoota P, Nguitragool W, Matsee W, Piyaphanee W, Shioda T (2022) Spread of a novel Indian ocean lineage carrying E1\u2013K211E\/E2-V264A of chikungunya virus east\/central\/south African genotype across the Indian subcontinent, Southeast Asia, and Eastern Africa. Microorganisms 10(2):354. https:\/\/doi.org\/10.3390\/microorganisms10020354","journal-title":"Microorganisms"},{"issue":"13","key":"11131_CR112","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1056\/NEJMra1406035","volume":"372","author":"SC Weaver","year":"2015","unstructured":"Weaver SC, Lecuit M (2015) Chikungunya virus and the global spread of a mosquito-borne disease. N Engl J Med 372(13):1231\u20131239. https:\/\/doi.org\/10.1056\/NEJMra1406035","journal-title":"N Engl J Med"},{"issue":"5","key":"11131_CR113","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/v10050268","volume":"10","author":"P Roques","year":"2018","unstructured":"Roques P, Thiberville S-D, Dupuis-Maguiraga L, Lum F-M, Labadie K, Martinon F, Gras G, Lebon P, Ng LFP, De Lamballerie X, Le Grand R (2018) Paradoxical effect of chloroquine treatment in enhancing chikungunya virus infection. Viruses 10(5):268. https:\/\/doi.org\/10.3390\/v10050268","journal-title":"Viruses"},{"key":"11131_CR114","doi-asserted-by":"publisher","first-page":"110934","DOI":"10.1016\/j.msec.2020.110934","volume":"112","author":"S Choudhary","year":"2020","unstructured":"Choudhary S, Kumar R, Dalal U, Tomar S, Reddy SN (2020) Green synthesis of nanometal impregnated biomass\u2014antiviral potential. Mater Sci Eng, C 112:110934. https:\/\/doi.org\/10.1016\/j.msec.2020.110934","journal-title":"Mater Sci Eng, C"},{"issue":"7","key":"11131_CR115","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.3201\/eid2207.151990","volume":"22","author":"AR Plourde","year":"2016","unstructured":"Plourde AR, Bloch EM (2016) A literature review of Zika virus. Emerg Infect Dis 22(7):1185\u20131192. https:\/\/doi.org\/10.3201\/eid2207.151990","journal-title":"Emerg Infect Dis"},{"issue":"5","key":"11131_CR116","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jiph.2018.04.007","volume":"11","author":"R Noor","year":"2018","unstructured":"Noor R, Ahmed T (2018) Zika virus: epidemiological study and its association with public health risk. J Infect Public Health 11(5):611\u2013616. https:\/\/doi.org\/10.1016\/j.jiph.2018.04.007","journal-title":"J Infect Public Health"},{"issue":"12","key":"11131_CR117","doi-asserted-by":"publisher","first-page":"322","DOI":"10.3390\/v8120322","volume":"8","author":"R Delvecchio","year":"2016","unstructured":"Delvecchio R, Higa L, Pezzuto P, Valad\u00e3o A, Garcez P, Monteiro F, Loiola E, Dias A, Silva F, Aliota M, Caine E, Osorio J, Bellio M, O\u2019Connor D, Rehen S, De Aguiar R, Savarino A, Campanati L, Tanuri A (2016) Chloroquine, an endocytosis blocking agent, inhibits Zika virus infection in different cell models. Viruses 8(12):322. https:\/\/doi.org\/10.3390\/v8120322","journal-title":"Viruses"},{"key":"11131_CR118","doi-asserted-by":"publisher","first-page":"104547","DOI":"10.1016\/j.antiviral.2019.104547","volume":"169","author":"S Zhang","year":"2019","unstructured":"Zhang S, Yi C, Li C, Zhang F, Peng J, Wang Q, Liu X, Ye X, Li P, Wu M, Yan Q, Guo W, Niu X, Feng L, Pan W, Chen L, Qu L (2019) Chloroquine inhibits endosomal viral RNA release and autophagy-dependent viral replication and effectively prevents maternal to fetal transmission of Zika virus. Antiviral Res 169:104547. https:\/\/doi.org\/10.1016\/j.antiviral.2019.104547","journal-title":"Antiviral Res"},{"issue":"1","key":"11131_CR119","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.xphs.2018.10.056","volume":"108","author":"O Olafuyi","year":"2019","unstructured":"Olafuyi O, Badhan RKS (2019) Dose optimization of chloroquine by pharmacokinetic modeling during pregnancy for the treatment of Zika virus infection. J Pharm Sci 108(1):661\u2013673. https:\/\/doi.org\/10.1016\/j.xphs.2018.10.056","journal-title":"J Pharm Sci"},{"issue":"5","key":"11131_CR120","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.3390\/microorganisms11051097","volume":"11","author":"EJ Franco","year":"2023","unstructured":"Franco EJ, Hanrahan KC, Brown AN (2023) Favipiravir Inhibits Zika virus (ZIKV) replication in HeLa cells by altering viral infectivity. Microorganisms 11(5):1097. https:\/\/doi.org\/10.3390\/microorganisms11051097","journal-title":"Microorganisms"},{"issue":"2","key":"11131_CR121","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/v10020072","volume":"10","author":"J-A Kim","year":"2018","unstructured":"Kim J-A, Seong R-K, Kumar M, Shin O (2018) Favipiravir and ribavirin inhibit replication of Asian and African strains of Zika virus in different cell models. Viruses 10(2):72. https:\/\/doi.org\/10.3390\/v10020072","journal-title":"Viruses"},{"issue":"1","key":"11131_CR122","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.diagmicrobio.2019.03.012","volume":"95","author":"H Ketkar","year":"2019","unstructured":"Ketkar H, Yang L, Wormser GP, Wang P (2019) Lack of efficacy of ivermectin for prevention of a lethal Zika virus infection in a murine system. Diagn Microbiol Infect Dis 95(1):38\u201340. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2019.03.012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"11131_CR123","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.antiviral.2017.04.016","volume":"143","author":"IC Albulescu","year":"2017","unstructured":"Albulescu IC, Kovacikova K, Tas A, Snijder EJ, van Hemert MJ (2017) Suramin inhibits Zika virus replication by interfering with virus attachment and release of infectious particles. Antiviral Res 143:230\u2013236. https:\/\/doi.org\/10.1016\/j.antiviral.2017.04.016","journal-title":"Antiviral Res"},{"issue":"8","key":"11131_CR124","doi-asserted-by":"publisher","first-page":"e0007681","DOI":"10.1371\/journal.pntd.0007681","volume":"13","author":"S Dong","year":"2019","unstructured":"Dong S, Kang S, Dimopoulos G (2019) Identification of anti-flaviviral drugs with mosquitocidal and anti-Zika virus activity in Aedes aegypti. PLoS Negl Trop Dis 13(8):e0007681. https:\/\/doi.org\/10.1371\/journal.pntd.0007681","journal-title":"PLoS Negl Trop Dis"},{"issue":"10","key":"11131_CR125","doi-asserted-by":"publisher","first-page":"S945","DOI":"10.1093\/infdis\/jix406","volume":"216","author":"X Xie","year":"2017","unstructured":"Xie X, Zou J, Shan C, Shi P-Y (2017) Small molecules and antibodies for Zika therapy. J Infect Dis 216(10):S945\u2013S950. https:\/\/doi.org\/10.1093\/infdis\/jix406","journal-title":"J Infect Dis"},{"issue":"14","key":"11131_CR126","doi-asserted-by":"publisher","first-page":"7981","DOI":"10.1073\/pnas.2000414117","volume":"117","author":"KKA Van Rompay","year":"2020","unstructured":"Van Rompay KKA, Coffey LL, Kapoor T, Gazumyan A, Keesler RI, Jurado A, Peace A, Agudelo M, Watanabe J, Usachenko J, Singapuri A, Immareddy R, Ardeshir A, Stuart JB, Bournazos S, Ravetch JV, Balderes PJ, Lorenz IC, Esswein SR et al (2020) A combination of two human monoclonal antibodies limits fetal damage by Zika virus in macaques. Proc Natl Acad Sci 117(14):7981\u20137989. https:\/\/doi.org\/10.1073\/pnas.2000414117","journal-title":"Proc Natl Acad Sci"},{"issue":"4","key":"11131_CR127","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1128\/CMR.00035-09","volume":"22","author":"BEE Martina","year":"2009","unstructured":"Martina BEE, Koraka P, Osterhaus ADME (2009) Dengue virus pathogenesis: an integrated view. Clin Microbiol Rev 22(4):564\u2013581. https:\/\/doi.org\/10.1128\/CMR.00035-09","journal-title":"Clin Microbiol Rev"},{"issue":"3","key":"11131_CR128","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1007\/s40121-021-00470-2","volume":"10","author":"M Du","year":"2021","unstructured":"Du M, Jing W, Liu M, Liu J (2021) The global trends and regional differences in incidence of dengue infection from 1990 to 2019: an analysis from the Global Burden of Disease Study 2019. Infect Dis Ther 10(3):1625\u20131643. https:\/\/doi.org\/10.1007\/s40121-021-00470-2","journal-title":"Infect Dis Ther"},{"issue":"1","key":"11131_CR129","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2013\/282734","volume":"2013","author":"KJS Farias","year":"2013","unstructured":"Farias KJS, Machado PRL, da Fonseca BAL (2013) Chloroquine inhibits dengue virus type 2 replication in Vero cells but not in C6\/36 cells. Sci World J 2013(1):1. https:\/\/doi.org\/10.1155\/2013\/282734","journal-title":"Sci World J"},{"issue":"6","key":"11131_CR130","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/1348-0421.12154","volume":"58","author":"KJS Farias","year":"2014","unstructured":"Farias KJS, Machado PRL, de Almeida Junior RF, de Aquino AA, da Fonseca BAL (2014) Chloroquine interferes with dengue-2 virus replication in U937 cells. Microbiol Immunol 58(6):318\u2013326. https:\/\/doi.org\/10.1111\/1348-0421.12154","journal-title":"Microbiol Immunol"},{"issue":"3","key":"11131_CR131","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1089\/vim.2014.0090","volume":"28","author":"KJS Farias","year":"2015","unstructured":"Farias KJS, Machado PRL, Muniz JAPC, Imbeloni AA, da Fonseca BAL (2015) Antiviral activity of chloroquine against dengue virus type 2 replication in Aotus monkeys. Viral Immunol 28(3):161\u2013169. https:\/\/doi.org\/10.1089\/vim.2014.0090","journal-title":"Viral Immunol"},{"issue":"4","key":"11131_CR132","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1159\/000321892","volume":"54","author":"M Mart\u00ednez-Gutierrez","year":"2011","unstructured":"Mart\u00ednez-Gutierrez M, Castellanos JE, Gallego-G\u00f3mez JC (2011) Statins reduce dengue virus production via decreased Virion assembly. Intervirology 54(4):202\u2013216. https:\/\/doi.org\/10.1159\/000321892","journal-title":"Intervirology"},{"issue":"1\u20132","key":"11131_CR133","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.virol.2009.03.025","volume":"389","author":"C Rothwell","year":"2009","unstructured":"Rothwell C, LeBreton A, Young Ng C, Lim JYH, Liu W, Vasudevan S, Labow M, Gu F, Gaither LA (2009) Cholesterol biosynthesis modulation regulates dengue viral replication. Virology 389(1\u20132):8\u201319. https:\/\/doi.org\/10.1016\/j.virol.2009.03.025","journal-title":"Virology"},{"key":"11131_CR134","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coph.2016.06.002","volume":"30","author":"SJ Kaptein","year":"2016","unstructured":"Kaptein SJ, Neyts J (2016) Towards antiviral therapies for treating dengue virus infections. Curr Opin Pharmacol 30:1\u20137. https:\/\/doi.org\/10.1016\/j.coph.2016.06.002","journal-title":"Curr Opin Pharmacol"},{"issue":"10","key":"11131_CR135","doi-asserted-by":"publisher","first-page":"e594","DOI":"10.1093\/cid\/ciaa1341","volume":"72","author":"EE Ooi","year":"2021","unstructured":"Ooi EE (2021) Repurposing ivermectin as an anti-dengue drug. Clin Infect Dis 72(10):e594\u2013e595. https:\/\/doi.org\/10.1093\/cid\/ciaa1341","journal-title":"Clin Infect Dis"},{"key":"11131_CR136","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.antiviral.2014.07.014","volume":"110","author":"J-F Rossignol","year":"2014","unstructured":"Rossignol J-F (2014) Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res 110:94\u2013103. https:\/\/doi.org\/10.1016\/j.antiviral.2014.07.014","journal-title":"Antiviral Res"},{"key":"11131_CR137","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.virusres.2018.07.018","volume":"255","author":"S Malakar","year":"2018","unstructured":"Malakar S, Sreelatha L, Dechtawewat T, Noisakran S, Yenchitsomanus P, Chu JJH, Limjindaporn T (2018) Drug repurposing of quinine as antiviral against dengue virus infection. Virus Res 255:171\u2013178. https:\/\/doi.org\/10.1016\/j.virusres.2018.07.018","journal-title":"Virus Res"},{"issue":"1","key":"11131_CR138","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.bbrc.2016.07.029","volume":"478","author":"SL Leela","year":"2016","unstructured":"Leela SL, Srisawat C, Sreekanth GP, Noisakran S, Yenchitsomanus P, Limjindaporn T (2016) Drug repurposing of minocycline against dengue virus infection. Biochem Biophys Res Commun 478(1):410\u2013416. https:\/\/doi.org\/10.1016\/j.bbrc.2016.07.029","journal-title":"Biochem Biophys Res Commun"},{"issue":"11","key":"11131_CR139","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1007\/s00705-022-05555-y","volume":"167","author":"LE Piccini","year":"2022","unstructured":"Piccini LE, Castilla V, Damonte EB (2022) Inhibition of dengue virus infection by trifluoperazine. Adv Virol 167(11):2203\u20132212. https:\/\/doi.org\/10.1007\/s00705-022-05555-y","journal-title":"Adv Virol"},{"key":"11131_CR140","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.antiviral.2019.03.011","volume":"166","author":"GP Sreekanth","year":"2019","unstructured":"Sreekanth GP, Panaampon J, Suttitheptumrong A, Chuncharunee A, Bootkunha J, Yenchitsomanus P, Limjindaporn T (2019) Drug repurposing of N-acetyl cysteine as antiviral against dengue virus infection. Antiviral Res 166:42\u201355. https:\/\/doi.org\/10.1016\/j.antiviral.2019.03.011","journal-title":"Antiviral Res"},{"issue":"1","key":"11131_CR141","doi-asserted-by":"publisher","first-page":"10136","DOI":"10.1038\/s41598-021-89171-x","volume":"11","author":"T Amemiya","year":"2021","unstructured":"Amemiya T, Horimoto K, Fukui K (2021) Application of multiple omics and network projection analyses to drug repositioning for pathogenic mosquito-borne viruses. Sci Rep 11(1):10136. https:\/\/doi.org\/10.1038\/s41598-021-89171-x","journal-title":"Sci Rep"},{"issue":"1","key":"11131_CR142","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.cll.2009.10.006","volume":"30","author":"SL Rossi","year":"2010","unstructured":"Rossi SL, Ross TM, Evans JD (2010) West Nile virus. Clin Lab Med 30(1):47\u201365. https:\/\/doi.org\/10.1016\/j.cll.2009.10.006","journal-title":"Clin Lab Med"},{"key":"11131_CR143","doi-asserted-by":"publisher","first-page":"100994","DOI":"10.1016\/j.mam.2021.100994","volume":"81","author":"KB Sharma","year":"2021","unstructured":"Sharma KB, Vrati S, Kalia M (2021) Pathobiology of Japanese encephalitis virus infection. Mol Aspects Med 81:100994. https:\/\/doi.org\/10.1016\/j.mam.2021.100994","journal-title":"Mol Aspects Med"},{"issue":"11","key":"11131_CR144","doi-asserted-by":"publisher","first-page":"2480","DOI":"10.3390\/v14112480","volume":"14","author":"JS Mackenzie","year":"2022","unstructured":"Mackenzie JS, Williams DT, van den Hurk AF, Smith DW, Currie BJ (2022) Japanese encephalitis virus: the emergence of genotype IV in Australia and its potential endemicity. Viruses 14(11):2480. https:\/\/doi.org\/10.3390\/v14112480","journal-title":"Viruses"},{"issue":"1","key":"11131_CR145","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/22221751.2021.1941276","volume":"10","author":"L Huang","year":"2021","unstructured":"Huang L, Li H, Ye Z, Xu Q, Fu Q, Sun W, Qi W, Yue J (2021) Berbamine inhibits Japanese encephalitis virus (JEV) infection by compromising TPRMLs-mediated endolysosomal trafficking of low-density lipoprotein receptor (LDLR). Emerg Microbes Infect 10(1):1257\u20131271. https:\/\/doi.org\/10.1080\/22221751.2021.1941276","journal-title":"Emerg Microbes Infect"},{"issue":"2","key":"11131_CR146","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s43440-022-00355-2","volume":"74","author":"S Joe","year":"2022","unstructured":"Joe S, Salam AAA, Neogi U, Naren Babu N, Mudgal PP (2022) Antiviral drug research for Japanese encephalitis: an updated review. Pharmacol Rep 74(2):273\u2013296. https:\/\/doi.org\/10.1007\/s43440-022-00355-2","journal-title":"Pharmacol Rep"},{"key":"11131_CR147","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.virusres.2019.02.006","volume":"263","author":"Y Guo","year":"2019","unstructured":"Guo Y, Duan M, Wang X, Gao J, Guan Z, Zhang M (2019) Early events in rabies virus infection\u2014attachment, entry, and intracellular trafficking. Virus Res 263:217\u2013225. https:\/\/doi.org\/10.1016\/j.virusres.2019.02.006","journal-title":"Virus Res"},{"issue":"1","key":"11131_CR148","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3851\/IMP2851","volume":"20","author":"CM Appolinario","year":"2015","unstructured":"Appolinario CM, Jackson AC (2015) Antiviral Therapy for Human Rabies. Antivir Ther 20(1):1\u201310. https:\/\/doi.org\/10.3851\/IMP2851","journal-title":"Antivir Ther"},{"key":"11131_CR149","doi-asserted-by":"publisher","DOI":"10.1128\/mSphere.00598-20","author":"M Marklewitz","year":"2020","unstructured":"Marklewitz M, Tchouassi DP, Hieke C, Heyde V, Torto B, Sang R, Junglen S (2020) Insights into the evolutionary origin of Mediterranean sandfly fever viruses. MSphere. https:\/\/doi.org\/10.1128\/mSphere.00598-20","journal-title":"MSphere"},{"issue":"5","key":"11131_CR150","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s12276-021-00610-1","volume":"53","author":"MA Casel","year":"2021","unstructured":"Casel MA, Park SJ, Choi YK (2021) Severe fever with thrombocytopenia syndrome virus: emerging novel phlebovirus and their control strategy. Exp Mol Med 53(5):713\u2013722. https:\/\/doi.org\/10.1038\/s12276-021-00610-1","journal-title":"Exp Mol Med"},{"issue":"1","key":"11131_CR151","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1080\/1040841X.2020.1847037","volume":"47","author":"J Li","year":"2021","unstructured":"Li J, Li S, Yang L, Cao P, Lu J (2021) Severe fever with thrombocytopenia syndrome virus: a highly lethal bunyavirus. Crit Rev Microbiol 47(1):112\u2013125. https:\/\/doi.org\/10.1080\/1040841X.2020.1847037","journal-title":"Crit Rev Microbiol"},{"issue":"5","key":"11131_CR152","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1007\/s12250-019-00162-9","volume":"34","author":"S Liu","year":"2019","unstructured":"Liu S, Liu H, Zhang K, Li X, Duan Y, Wang Z, Wang T (2019) Proteasome inhibitor PS-341 effectively blocks infection by the severe fever with thrombocytopenia syndrome virus. Virol Sinica 34(5):572\u2013582. https:\/\/doi.org\/10.1007\/s12250-019-00162-9","journal-title":"Virol Sinica"},{"issue":"9","key":"11131_CR153","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1038\/s41422-019-0214-z","volume":"29","author":"H Li","year":"2019","unstructured":"Li H, Zhang L-K, Li S-F, Zhang S-F, Wan W-W, Zhang Y-L, Xin Q-L, Dai K, Hu Y-Y, Wang Z-B, Zhu X-T, Fang Y-J, Cui N, Zhang P-H, Yuan C, Lu Q-B, Bai J-Y, Deng F, Xiao G-F et al (2019) Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality. Cell Res 29(9):739\u2013753. https:\/\/doi.org\/10.1038\/s41422-019-0214-z","journal-title":"Cell Res"},{"issue":"4","key":"11131_CR154","doi-asserted-by":"publisher","first-page":"385","DOI":"10.3390\/v11040385","volume":"11","author":"S Yuan","year":"2019","unstructured":"Yuan S, Chan JF-W, Ye Z-W, Wen L, Tsang TG-W, Cao J, Huang J, Chan CC-Y, Chik KK-H, Choi GK-Y, Cai J-P, Yin F, Chu H, Liang M, Jin D-Y, Yuen K-Y (2019) Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus. Viruses 11(4):385. https:\/\/doi.org\/10.3390\/v11040385","journal-title":"Viruses"},{"issue":"2","key":"11131_CR155","doi-asserted-by":"publisher","first-page":"e1007375","DOI":"10.1371\/journal.ppat.1007375","volume":"15","author":"KH Kim","year":"2019","unstructured":"Kim KH, Kim J, Ko M, Chun JY, Kim H, Kim S, Min J-Y, Park WB, Oh M, Chung J (2019) An anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the infection of severe fever with thrombocytopenia syndrome virus. PLoS Pathog 15(2):e1007375. https:\/\/doi.org\/10.1371\/journal.ppat.1007375","journal-title":"PLoS Pathog"},{"issue":"8","key":"11131_CR156","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1099\/jgv.0.001296","volume":"100","author":"D Wright","year":"2019","unstructured":"Wright D, Kortekaas J, Bowden TA, Warimwe GM (2019) Rift Valley fever: biology and epidemiology. J Gen Virol 100(8):1187\u20131199. https:\/\/doi.org\/10.1099\/jgv.0.001296","journal-title":"J Gen Virol"},{"issue":"12","key":"11131_CR157","doi-asserted-by":"publisher","first-page":"7405","DOI":"10.1128\/AAC.03595-14","volume":"58","author":"M Ellenbecker","year":"2014","unstructured":"Ellenbecker M, Lanchy J-M, Lodmell JS (2014) Inhibition of rift valley fever virus replication and perturbation of nucleocapsid-RNA interactions by Suramin. Antimicrob Agents Chemother 58(12):7405\u20137415. https:\/\/doi.org\/10.1128\/AAC.03595-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"11131_CR158","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1016\/j.medmal.2019.09.005","volume":"49","author":"P Fill\u00e2tre","year":"2019","unstructured":"Fill\u00e2tre P, Revest M, Tattevin P (2019) Crimean-Congo hemorrhagic fever: an update. Med Mal Infect 49(8):574\u2013585. https:\/\/doi.org\/10.1016\/j.medmal.2019.09.005","journal-title":"Med Mal Infect"},{"issue":"7","key":"11131_CR159","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.3390\/v13071195","volume":"13","author":"S Dai","year":"2021","unstructured":"Dai S, Deng F, Wang H, Ning Y (2021) Crimean-Congo hemorrhagic fever virus: current advances and future prospects of antiviral strategies. Viruses 13(7):1195. https:\/\/doi.org\/10.3390\/v13071195","journal-title":"Viruses"},{"key":"11131_CR160","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.antiviral.2015.03.005","volume":"118","author":"O Ferraris","year":"2015","unstructured":"Ferraris O, Moroso M, Pernet O, Emonet S, Ferrier Rembert A, Paranhos-Baccal\u00e0 G, Peyrefitte CN (2015) Evaluation of Crimean-Congo hemorrhagic fever virus in vitro inhibition by chloroquine and chlorpromazine, two FDA approved molecules. Antiviral Res 118:75\u201381. https:\/\/doi.org\/10.1016\/j.antiviral.2015.03.005","journal-title":"Antiviral Res"},{"key":"11131_CR161","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1083429","author":"E Taki","year":"2023","unstructured":"Taki E, Ghanavati R, Navidifar T, Dashtbin S, Heidary M, Moghadamnia M (2023) EbangaTM: The most recent FDA-approved drug for treating Ebola. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2023.1083429","journal-title":"Front Pharmacol"},{"issue":"1","key":"11131_CR162","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s40265-020-01452-3","volume":"81","author":"A Markham","year":"2021","unstructured":"Markham A (2021) REGN-EB3: first approval. Drugs 81(1):175\u2013178. https:\/\/doi.org\/10.1007\/s40265-020-01452-3","journal-title":"Drugs"},{"issue":"19","key":"11131_CR163","doi-asserted-by":"publisher","first-page":"10338","DOI":"10.1128\/JVI.01196-12","volume":"86","author":"Y Kan","year":"2012","unstructured":"Kan Y, Okabayashi T, Yokota S, Yamamoto S, Fujii N, Yamashita T (2012) Imiquimod suppresses propagation of herpes simplex virus 1 by upregulation of cystatin A via the adenosine receptor A1 pathway. J Virol 86(19):10338\u201310346. https:\/\/doi.org\/10.1128\/JVI.01196-12","journal-title":"J Virol"},{"key":"11131_CR164","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.antiviral.2018.07.006","volume":"157","author":"T Schr\u00e4der","year":"2018","unstructured":"Schr\u00e4der T, Dudek SE, Schreiber A, Ehrhardt C, Planz O, Ludwig S (2018) The clinically approved MEK inhibitor Trametinib efficiently blocks influenza A virus propagation and cytokine expression. Antiviral Res 157:80\u201392. https:\/\/doi.org\/10.1016\/j.antiviral.2018.07.006","journal-title":"Antiviral Res"},{"key":"11131_CR165","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/872370","volume":"2014","author":"P Mehrbod","year":"2014","unstructured":"Mehrbod P, Omar AR, Hair-Bejo M, Haghani A, Ideris A (2014) Mechanisms of action and efficacy of statins against influenza. Biomed Res Int 2014:1\u20138. https:\/\/doi.org\/10.1155\/2014\/872370","journal-title":"Biomed Res Int"},{"issue":"8","key":"11131_CR166","doi-asserted-by":"publisher","first-page":"9516","DOI":"10.1096\/fj.201900428RR","volume":"33","author":"D Episcopio","year":"2019","unstructured":"Episcopio D, Aminov S, Benjamin S, Germain G, Datan E, Landazuri J, Lockshin RA, Zakeri Z (2019) Atorvastatin restricts the ability of influenza virus to generate lipid droplets and severely suppresses the replication of the virus. FASEB J 33(8):9516\u20139525. https:\/\/doi.org\/10.1096\/fj.201900428RR","journal-title":"FASEB J"},{"issue":"7","key":"11131_CR167","doi-asserted-by":"publisher","first-page":"e11610","DOI":"10.1371\/journal.pone.0011610","volume":"5","author":"MA Carey","year":"2010","unstructured":"Carey MA, Bradbury JA, Rebolloso YD, Graves JP, Zeldin DC, Germolec DR (2010) Pharmacologic inhibition of COX-1 and COX-2 in influenza A viral infection in Mice. PLoS ONE 5(7):e11610. https:\/\/doi.org\/10.1371\/journal.pone.0011610","journal-title":"PLoS ONE"},{"issue":"5","key":"11131_CR168","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1128\/AAC.02335-12","volume":"57","author":"N Lejal","year":"2013","unstructured":"Lejal N, Tarus B, Bouguyon E, Chenavas S, Bertho N, Delmas B, Ruigrok RWH, Di Primo C, Slama-Schwok A (2013) Structure-based discovery of the novel antiviral properties of naproxen against the nucleoprotein of influenza A virus. Antimicrob Agents Chemother 57(5):2231\u20132242. https:\/\/doi.org\/10.1128\/AAC.02335-12","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"11131_CR169","doi-asserted-by":"publisher","first-page":"1977","DOI":"10.1128\/AAC.02496-13","volume":"58","author":"C Gavegnano","year":"2014","unstructured":"Gavegnano C, Detorio M, Montero C, Bosque A, Planelles V, Schinazi RF (2014) Ruxolitinib and Tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother 58(4):1977\u20131986. https:\/\/doi.org\/10.1128\/AAC.02496-13","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"11131_CR170","doi-asserted-by":"publisher","first-page":"e20284","DOI":"10.1016\/j.heliyon.2023.e20284","volume":"9","author":"HS Lee","year":"2023","unstructured":"Lee HS, Noh JY, Song JY, Cheong HJ, Kim WJ (2023) Metformin reduces the risk of developing influenza A virus related cardiovascular disease. Heliyon 9(10):e20284. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e20284","journal-title":"Heliyon"},{"issue":"3","key":"11131_CR171","doi-asserted-by":"publisher","first-page":"436","DOI":"10.3947\/ic.2020.0126","volume":"53","author":"JR Quiros","year":"2021","unstructured":"Quiros JR, Ross-Comptis J, Hathaway D, Sarfraz A, Sarfraz Z, Grigoryan Z, Romero KA, Gapizov A, Pr\u00edncipe-Meneses FS, Somagutta MR, Riva-Moscoso A, Kapasi A (2021) Ruxolitinib and the mitigation of severe COVID-19: a systematic review and meta-analysis. Infect Chemother 53(3):436. https:\/\/doi.org\/10.3947\/ic.2020.0126","journal-title":"Infect Chemother"},{"issue":"3","key":"11131_CR172","doi-asserted-by":"publisher","first-page":"201","DOI":"10.2174\/1570163814666170727130003","volume":"15","author":"A Shakya","year":"2018","unstructured":"Shakya A, Bhat HR, Ghosh SK (2018) Update on nitazoxanide: a multifunctional chemotherapeutic agent. Curr Drug Discov Technol 15(3):201\u2013213. https:\/\/doi.org\/10.2174\/1570163814666170727130003","journal-title":"Curr Drug Discov Technol"},{"issue":"70","key":"11131_CR173","doi-asserted-by":"publisher","first-page":"115315","DOI":"10.18632\/oncotarget.23258","volume":"8","author":"K Lee","year":"2017","unstructured":"Lee K, Kim D-E, Jang K-S, Kim S-J, Cho S, Kim C (2017) Gemcitabine, a broad-spectrum antiviral drug, suppresses enterovirus infections through innate immunity induced by the inhibition of pyrimidine biosynthesis and nucleotide depletion. Oncotarget 8(70):115315\u2013115325. https:\/\/doi.org\/10.18632\/oncotarget.23258","journal-title":"Oncotarget"},{"key":"11131_CR174","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2022.979904","author":"Y Mao","year":"2022","unstructured":"Mao Y, Wang Z, Yao C, Zeng Q, Cheng W, Zhang S, Chen S, Sheng C (2022) The Food and Drug Administration-approved antipsychotic drug trifluoperazine, a calmodulin antagonist, inhibits viral replication through PERK-eIF2\u03b1 axis. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2022.979904","journal-title":"Front Microbiol"},{"issue":"3","key":"11131_CR175","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.bsheal.2022.05.002","volume":"4","author":"W Yuan","year":"2022","unstructured":"Yuan W, Dong X, Chen L, Lei X, Zhou Z, Guo L, Wang J (2022) Screening for inhibitors against SARS-CoV-2 and its variants. Biosaf Health 4(3):186\u2013192. https:\/\/doi.org\/10.1016\/j.bsheal.2022.05.002","journal-title":"Biosaf Health"},{"issue":"1","key":"11131_CR176","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41598-018-36636-1","volume":"9","author":"T Amemiya","year":"2019","unstructured":"Amemiya T, Gromiha MM, Horimoto K, Fukui K (2019) Drug repositioning for dengue haemorrhagic fever by integrating multiple omics analyses. Sci Rep 9(1):523. https:\/\/doi.org\/10.1038\/s41598-018-36636-1","journal-title":"Sci Rep"},{"issue":"3","key":"11131_CR177","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/jmv.24660","volume":"89","author":"Y Han","year":"2017","unstructured":"Han Y, Penthala NR, Oliveira M, Mespl\u00e8de T, Xu H, Quan Y, Crooks PA, Wainberg MA (2017) Identification of resveratrol analogs as potent anti-dengue agents using a cell-based assay. J Med Virol 89(3):397\u2013407. https:\/\/doi.org\/10.1002\/jmv.24660","journal-title":"J Med Virol"},{"issue":"5","key":"11131_CR178","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1136\/thx.2010.150318","volume":"66","author":"SN Lauder","year":"2011","unstructured":"Lauder SN, Taylor PR, Clark SR, Evans RL, Hindley JP, Smart K, Leach H, Kidd EJ, Broadley KJ, Jones SA, Wise MP, Godkin AJ, O\u2019Donnell V, Gallimore AM (2011) Paracetamol reduces influenza-induced immunopathology in a mouse model of infection without compromising virus clearance or the generation of protective immunity. Thorax 66(5):368\u2013374. https:\/\/doi.org\/10.1136\/thx.2010.150318","journal-title":"Thorax"},{"issue":"5","key":"11131_CR179","doi-asserted-by":"publisher","first-page":"e0008336","DOI":"10.1371\/journal.pntd.0008336","volume":"14","author":"P Kaur","year":"2020","unstructured":"Kaur P, Lello LS, Utt A, Dutta SK, Merits A, Chu JJH (2020) Bortezomib inhibits chikungunya virus replication by interfering with viral protein synthesis. PLoS Negl Trop Dis 14(5):e0008336. https:\/\/doi.org\/10.1371\/journal.pntd.0008336","journal-title":"PLoS Negl Trop Dis"},{"key":"11131_CR180","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2020.00150","author":"M Takayama-Ito","year":"2020","unstructured":"Takayama-Ito M, Saijo M (2020) Antiviral drugs against severe fever with thrombocytopenia syndrome virus infection. Front Microbiol. https:\/\/doi.org\/10.3389\/fmicb.2020.00150","journal-title":"Front Microbiol"},{"issue":"1","key":"11131_CR181","doi-asserted-by":"publisher","first-page":"e1005308","DOI":"10.1371\/journal.pcbi.1005308","volume":"13","author":"KM Gayvert","year":"2017","unstructured":"Gayvert KM, Aly O, Platt J, Bosenberg MW, Stern DF, Elemento O (2017) A computational approach for identifying synergistic drug combinations. PLoS Comput Biol 13(1):e1005308. https:\/\/doi.org\/10.1371\/journal.pcbi.1005308","journal-title":"PLoS Comput Biol"},{"issue":"16","key":"11131_CR182","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1039\/D0CS01065K","volume":"50","author":"EN Muratov","year":"2021","unstructured":"Muratov EN, Amaro R, Andrade CH, Brown N, Ekins S, Fourches D, Isayev O, Kozakov D, Medina-Franco JL, Merz KM, Oprea TI, Poroikov V, Schneider G, Todd MH, Varnek A, Winkler DA, Zakharov AV, Cherkasov A, Tropsha A (2021) A critical overview of computational approaches employed for COVID-19 drug discovery. Chem Soc Rev 50(16):9121\u20139151. https:\/\/doi.org\/10.1039\/D0CS01065K","journal-title":"Chem Soc Rev"},{"issue":"1","key":"11131_CR183","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12915-021-01086-1","volume":"19","author":"J Rietdijk","year":"2021","unstructured":"Rietdijk J, Tampere M, Pettke A, Georgiev P, Lapins M, Warpman-Berglund U, Spjuth O, Puumalainen M-R, Carreras-Puigvert J (2021) A phenomics approach for antiviral drug discovery. BMC Biol 19(1):156. https:\/\/doi.org\/10.1186\/s12915-021-01086-1","journal-title":"BMC Biol"},{"issue":"1","key":"11131_CR184","doi-asserted-by":"publisher","first-page":"100039","DOI":"10.1016\/j.aichem.2023.100039","volume":"2","author":"S Singh","year":"2024","unstructured":"Singh S, Gupta H, Sharma P, Sahi S (2024) Advances in artificial intelligence (AI)-assisted approaches in drug screening. Artif Intell Chem 2(1):100039. https:\/\/doi.org\/10.1016\/j.aichem.2023.100039","journal-title":"Artif Intell Chem"},{"issue":"2","key":"11131_CR185","doi-asserted-by":"publisher","first-page":"e188","DOI":"10.7861\/fhj.2021-0095","volume":"8","author":"J Bajwa","year":"2021","unstructured":"Bajwa J, Munir U, Nori A, Williams B (2021) Artificial intelligence in healthcare: transforming the practice of medicine. Fut Healthcare J 8(2):e188\u2013e194. https:\/\/doi.org\/10.7861\/fhj.2021-0095","journal-title":"Fut Healthcare J"},{"issue":"3","key":"11131_CR186","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1517\/17460441.2016.1146250","volume":"11","author":"AN Lima","year":"2016","unstructured":"Lima AN, Philot EA, Trossini GHG, Scott LPB, Maltarollo VG, Honorio KM (2016) Use of machine learning approaches for novel drug discovery. Expert Opin Drug Discov 11(3):225\u2013239. https:\/\/doi.org\/10.1517\/17460441.2016.1146250","journal-title":"Expert Opin Drug Discov"},{"key":"11131_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fddsv.2024.1362456","author":"U Naithani","year":"2024","unstructured":"Naithani U, Guleria V (2024) Integrative computational approaches for discovery and evaluation of lead compound for drug design. Front Drug Discov. https:\/\/doi.org\/10.3389\/fddsv.2024.1362456","journal-title":"Front Drug Discov"},{"issue":"3","key":"11131_CR188","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.3390\/ijms25031364","volume":"25","author":"GM Nitulescu","year":"2024","unstructured":"Nitulescu GM (2024) Techniques and strategies in drug design and discovery. Int J Mol Sci 25(3):1364. https:\/\/doi.org\/10.3390\/ijms25031364","journal-title":"Int J Mol Sci"},{"issue":"1","key":"11131_CR189","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41564-018-0296-2","volume":"4","author":"ND Grubaugh","year":"2018","unstructured":"Grubaugh ND, Ladner JT, Lemey P, Pybus OG, Rambaut A, Holmes EC, Andersen KG (2018) Tracking virus outbreaks in the twenty-first century. Nat Microbiol 4(1):10\u201319. https:\/\/doi.org\/10.1038\/s41564-018-0296-2","journal-title":"Nat Microbiol"},{"issue":"1","key":"11131_CR190","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13690-023-01080-9","volume":"81","author":"H Utunen","year":"2023","unstructured":"Utunen H, Tokar A, Dancante M, Piroux C (2023) Online learning for WHO priority diseases with pandemic potential: evidence from existing courses and preparing for Disease X. Arch Public Health 81(1):61. https:\/\/doi.org\/10.1186\/s13690-023-01080-9","journal-title":"Arch Public Health"},{"key":"11131_CR191","doi-asserted-by":"publisher","first-page":"108345","DOI":"10.1016\/j.jmgm.2022.108345","volume":"118","author":"E Behmard","year":"2023","unstructured":"Behmard E, Ghasemian A, Barzegari E, Farjadfar A, Kouhpayeh A, Najafipour S (2023) Advanced simulations and screening to repurposing a 3C protease inhibitor against the rupintrivir-resistant human norovirus-induced gastroenteritis. J Mol Graph Model 118:108345. https:\/\/doi.org\/10.1016\/j.jmgm.2022.108345","journal-title":"J Mol Graph Model"},{"issue":"11","key":"11131_CR192","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41573-023-00774-7","volume":"22","author":"MW Mullowney","year":"2023","unstructured":"Mullowney MW, Duncan KR, Elsayed SS, Garg N, van der Hooft JJJ, Martin NI, Meijer D, Terlouw BR, Biermann F, Blin K, Durairaj J, Gorostiola Gonz\u00e1lez M, Helfrich EJN, Huber F, Leopold-Messer S, Rajan K, de Rond T, van Santen JA, Sorokina M et al (2023) Artificial intelligence for natural product drug discovery. Nat Rev Drug Discov 22(11):895\u2013916. https:\/\/doi.org\/10.1038\/s41573-023-00774-7","journal-title":"Nat Rev Drug Discov"},{"key":"11131_CR193","doi-asserted-by":"publisher","unstructured":"Tamura T, Zhang J, Madan V, Biswas A, Schwoerer MP, Cafiero TR, Heller BL, Wang W, Ploss A. Generation and characterization of genetically and antigenically diverse infectious clones of dengue virus serotypes 1-4. Emerg Microbes Infect. 2022;11(1):227-239. https:\/\/doi.org\/10.1080\/22221751.2021.2021808","DOI":"10.1080\/22221751.2021.2021808"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11131-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11131-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:29:36Z","timestamp":1763728176000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11131-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,18]]},"references-count":193,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["11131"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11131-8","relation":{},"ISSN":["1381-1991","1573-501X"],"issn-type":[{"value":"1381-1991","type":"print"},{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,18]]},"assertion":[{"value":"2 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}